{"id":"azithromycin-on-day-8","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"2-5","effect":"Abdominal pain"},{"rate":"1-3","effect":"Vomiting"},{"rate":"rare","effect":"QT prolongation"},{"rate":"rare","effect":"Hepatotoxicity"},{"rate":"1-2","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin is a macrolide antibiotic that binds to bacterial 23S rRNA within the 50S ribosomal subunit, preventing peptide bond formation and elongation of the bacterial polypeptide chain. This bacteriostatic action halts protein synthesis and allows the immune system to clear the infection. It also has immunomodulatory properties that may reduce inflammation in certain conditions.","oneSentence":"Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby stopping bacterial growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:28.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute otitis media"},{"name":"Pharyngitis/tonsillitis"},{"name":"Bronchitis"},{"name":"Skin and soft tissue infections"},{"name":"Sexually transmitted infections (chlamydia, gonorrhea)"}]},"trialDetails":[{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05398965","phase":"PHASE2","title":"Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)","status":"COMPLETED","sponsor":"Hasanuddin University","startDate":"2020-11-18","conditions":"COVID-19","enrollment":54},{"nctId":"NCT04977960","phase":"PHASE2","title":"Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-09","conditions":"COVID-19 Acute Respiratory Distress Syndrome","enrollment":180},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT04870138","phase":"PHASE1","title":"Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-10","conditions":"Gonococcal Infection","enrollment":16},{"nctId":"NCT04150250","phase":"PHASE2","title":"Cholera Anti-Secretory Treatment Trial","status":"COMPLETED","sponsor":"PATH","startDate":"2019-11-04","conditions":"Cholera","enrollment":47},{"nctId":"NCT04386447","phase":"PHASE2","title":"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","status":"WITHDRAWN","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2020-09-01","conditions":"Covid-19, Corona Virus Infection, SARS-CoV 2","enrollment":""},{"nctId":"NCT04349410","phase":"PHASE2, PHASE3","title":"The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","status":"COMPLETED","sponsor":"The Camelot Foundation","startDate":"2020-04-11","conditions":"CoVid 19 Positive","enrollment":1800},{"nctId":"NCT04542694","phase":"PHASE3","title":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-05-21","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04126304","phase":"","title":"Mycoplasma Infection Rate and Macrolides Resistance in Children With Acute Respiratory Tract Infection","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2019-11-28","conditions":"Respiratory Tract Infections","enrollment":2312},{"nctId":"NCT02775617","phase":"PHASE4","title":"Azithromycin - Ivermectin Mass Drug Administration for Skin Disease","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2016-07","conditions":"Scabies, Yaws, Impetigo","enrollment":1291},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":"Trachoma, Yaws, Lymphatic Filariases","enrollment":20000},{"nctId":"NCT03831269","phase":"NA","title":"Pityriasis Lichenoides Chronica, Role of Streptococcal Infection and Azithromycin","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-02","conditions":"Pityriasis Lichenoides","enrollment":30},{"nctId":"NCT02708992","phase":"PHASE1","title":"Cefixime / Azithromycin pK Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-28","conditions":"Gonorrhoea","enrollment":10},{"nctId":"NCT02115516","phase":"PHASE1","title":"Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2014-04","conditions":"Malaria, Plasmodium Falciparum Malaria","enrollment":67},{"nctId":"NCT02023554","phase":"NA","title":"Drug Interaction Study of Azithromycin and Theophylline","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":40},{"nctId":"NCT01903057","phase":"PHASE4","title":"Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2014-02","conditions":"Trachoma, Lymphatic Filariasis","enrollment":""},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zithromax"],"phase":"phase_3","status":"active","brandName":"Azithromycin on Day 8","genericName":"Azithromycin on Day 8","companyName":"Lihir Medical Centre","companyId":"lihir-medical-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby stopping bacterial growth. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute otitis media.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}